Brand-specific vaccine effectiveness against SARS-CoV-2 infection, hospitalization and mortality, in people aged 50-59 years in Spain

Monge, S.; Mazagatos, C.; Olmedo, C.; Rojas-Benedicto, A.; Simon, F.; Vega-Piris, L.; Sierra, M. J.; Limia, A.; Larrauri, A.

Monge, S.; Mazagatos, C.; Olmedo, C.; Rojas-Benedicto, A.; Simon, F.; Vega-Piris, L.; Sierra, M. J.; Limia, A.; Larrauri, A..

Revista Espanola de Salud Publica ; 96(e202209060), 2022.

Article in English | GIM | ID: covidwho-2317349

ABSTRACT

ABSTRACT

We compared brand-specific vaccine effectiveness during August 2021 in people born between 1962 and 1971, vaccinated during June. For symptomatic infection, protection was lower for Janssen (56%;53-59) or Astra Zeneca (68%;65-70), compared to Pfizer (78%;77- 78), AZ/Pfizer (86%;80-90) or Moderna (89%;88-90). VE against hospitalization ranged 86% for Janssen to 97-98% for other vaccines.

Keywords

brand name products; coronavirus disease 2019; disease prevention; efficacy; elderly; health protection; hospital admission; human diseases; immunity; immunization; vaccination; vaccines; viral diseases; immune sensitization; man; Severe acute respiratory syndrome coronavirus 2; Spain; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; European Union Countries; high income countries; Mediterranean Region; OECD Countries; Southern Europe; Europe; very high Human Development Index countries; aged; elderly people; older adults; senior citizens; SARS-CoV-2; viral infections

Search on Google

XML

Collection: Databases of international organizations Database: GIM Type of study: Experimental Studies Topics: Vaccines Language: English Journal: Revista Espanola de Salud Publica Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML